Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.47 |
| ▸ | AHCY | P23526 | 3/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 4/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26808212 | 0.88 | ADORA1 (0.50) | ADORA1AHCYDOT1LNT5EP2RY12 | |
| SCHEMBL26808329 | 0.88 | ADORA1 (0.50) | ADORA1AHCYDOT1LNT5EP2RY12 | |
| SCHEMBL19941990 | 0.85 | ATM (0.53) | ATMADORA1CARM1AHCYDOT1L | |
| SCHEMBL26808538 | 0.82 | ADORA1 (0.49) | ADORA1AHCYDOT1LNT5EP2RY12 | |
| SCHEMBL19146234 | 0.81 | ADORA1 (0.51) | ADORA1AHCYDOT1L | |
| SCHEMBL26808467 | 0.80 | ADORA1 (0.49) | ADORA1AHCYDOT1L | |
| SCHEMBL25496503 | 0.79 | ADORA1 (0.57) | ADORA1AHCYDOT1L | |
| SCHEMBL15087031 | 0.79 | ADORA1 (0.57) | ADORA1AHCYDOT1L | |
| SCHEMBL15087043 | 0.79 | ADORA1 (0.57) | ADORA1AHCYDOT1L | |
| SCHEMBL15087047 | 0.79 | ADORA1 (0.57) | ADORA1AHCYDOT1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018045204-A1 | CYCLIC DINUCLEOTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH STING (STIMULATOR OF INTERFERON GENES) ACTIVITY | IFM THERAPEUTICS, INC (US) | 2018-03-08 | — | — | WO | disclosed |